ClinicalTrials.gg
RecruitingNCT07432022Updated Sep 1, 2026

A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

A Phase 1/2 interventional study of EMB07 and Rituximab/Gemcitabine/Oxaliplatin in Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma and EMB07, sponsored by Shanghai EpimAb Biotherapeutics Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Shanghai EpimAb Biotherapeutics Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
115
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is an open-label, multicenter, Phase I/II study designed to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of EMB-07 combination therapy in adult patients with aggressive B-cell non-Hodgkin lymphoma (B-NHL). The study consists two phases: Phase I of dose escalation and Phase II of dose expansion. Approximately 115 patients will be enrolled in this study (i.e., 5 cohorts of approximately 23 patients per cohort). Multiple EMB-07-based combination regimens will be evaluated in patients with relapsed/refractory (R/R) aggressive B-NHL (Cohort A) and patients with newly diagnosed aggressive B-NHL (Cohort B).

02

Conditions studied

  • Combination Therapy
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • EMB07
  • phaseI/II
03

In context

Lead sponsor

Shanghai EpimAb Biotherapeutics Co., Ltd. is the lead sponsor of 10 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Ability to understand and voluntarily sign the Form (ICF);
  2. Patients aged ≥18 years;
  3. > 12 weeks;
  4. performance status score: ≤1 point during the dose escalation phase, ≤2 points during the dose expansion phase.
  5. Cohort A: confirmed aggressive R/R B-NHL, including DLBCL, not otherwise specified (NOS), or DLBCL transformed from indolent lymphoma (e.g., follicular lymphoma) (t-DLBCL), or other aggressive B-NHL judged to potentially benefit from study treatment by the investigator and sponsor (e.g., high-grade B-cell lymphoma [HGBL], Richter transformation, other large B-cell lymphoma subtypes).

Cohort B: Newly diagnosed, treatment-naïve DLBCL NOS confirmed by pathology, or t-DLBCL not previously treated with adequate (at least 2 cycles) R-CHOP therapy (excluding Richter transformation or HGBL with BCL2/MYC±BCL6 rearrangements). Patients with newly diagnosed DLBCL NOS should have an International Prognostic Index (IPI) score ≥2 and Ann Arbor stage ≥2. The sponsor will reserve the right to limit the number of t-DLBCL patients enrolled in the study. Other aggressive B-NHLs patients who may benefit from the study treatment can be enrolled after careful risk/benefit assessment by the sponsor and investigator.

Exclusion criteria

Exclusion Criteria:

  1. Current or prior central nervous system (CNS) or meningeal involvement related to the underlying disease.
  2. Cohort A: Prior exposure to any ROR1-targeted agent (e.g., biologic or CAR-T); or Cohort A1: Prior exposure to Gemcitabine-based chemotherapy (≥ 2 consecutive cycles); or Cohort A2: Prior exposure to Polatuzumab Vedotin; or Cohorts A3 and A4: to prior Lenalidomide/Zanubrutinib or Chidamide therapy, respectively.
  3. to any agent included in the combination therapy regimen.
  4. Cohort A: Candidates suitable for or CAR-T cell therapy.
  5. Cohort A: Use of any standard or therapy for the underlying disease within 28 days before C1D1 or 5 half-lives (whichever is shorter), including chemotherapy, immunotherapy, radioimmunotherapy, non-palliative radiotherapy, or any other anti-tumor therapy. Only palliative radiotherapy to non-target lesions will be permitted.
  6. Cohort B: B-NHL with prior receipt of at least 2 consecutive cycles of R-CHOP (prior lymph node or local radiotherapy will not be an exclusion criterion).
  7. Major surgery or administration within 28 days prior to C1D1.
  8. History of allogeneic hematopoietic stem cell transplantation or solid organ transplantation (except corneal transplantation). In addition, patients who received ASCT within 3 months before C1D1, CAR-T within 6 months before C1D1, or diagnosed with (GVHD) will be excluded.
  9. Any AE related to prior therapy (excluding alopecia) that has not resolved to Grade ≤ 1 (per the [CTCAE], Version 5.0) or baseline at C1D1.
  10. Active virus (HBV) or virus (HCV) infection at screening. Patients with positive HBsAg and/or positive HBcAb but negative HBV DNA will be eligible for enrollment. Patients with positive HCV antibody but negative HCV RNA are also eligible for enrollment.
  11. Known positive serology or history of active viral infection
  12. Active infection requiring parenteral antibiotics, antivirals, or antifungals within 14 days before C1D1; prophylactic use of these agents (including parenteral administration) will be permitted.
  13. Prior requiring treatment or with evidence of recurrence within 5 years before C1D1 (except non-melanoma skin cancer or adequately treated carcinoma in situ of the cervix). Patients with a history of cancer treated with curative intent > 5 years before C1D1 and no evidence of recurrence will be eligible.
  14. Ischemic or hemorrhagic stroke of Grade ≥ 3, or gastrointestinal bleeding of Grade ≥ 3, within 6 months before C1D1.
  15. Active, unstable cardiovascular function:

    • Myocardial infarction within 6 months before C1D1;
    • Unstable angina within 3 months before C1D1;
    • uncontrolled arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes);
    • Mobitz type II second-degree or third-degree atrioventricular block;
    • Congestive heart failure at class ≥ 3 per (NYHA)
    • Known (LVEF) \< 50%.
  16. Known or suspected history of hemophagocytic lymphohistiocytosis (HLH);
  17. Known history of progressive multifocal leukoencephalopathy;
  18. Active disease requiring treatment

    • Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid hormone replacement will be eligible.
    • Type 1 diabetes mellitus well-controlled with insulin therapy will be permitted.
    • Patients with a history of autoimmune hepatitis, systemic lupus erythematosus, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, granulomatosis with polyangiitis, Sjögren's syndrome, multiple sclerosis, or glomerulonephritis will be excluded.
    • Patients with a history of immune thrombocytopenic purpura, autoimmune hemolytic anemia, Guillain-Barré syndrome, myasthenia gravis, myositis, rheumatoid arthritis, vasculitis, or other autoimmune diseases are excluded unless no systemic therapy has been required in the past 12 months.
  19. Prior systemic medication (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 28 days before C1D1.
  20. Systemic use within 2 weeks before study treatment at a dose equivalent to > 10 mg/day Prednisone. Inhaled, topical, or ophthalmic steroids will be permitted. Short-term corticosteroid use (e.g., prophylaxis for intravenous contrast) will be permitted.
  21. Any other severe underlying medical condition (e.g., active gastric ulcer, uncontrolled seizures, cerebrovascular event, gastrointestinal bleeding, coagulation/thrombotic disorders with severe signs/symptoms, cardiac disease), or psychiatric, psychological, familial, or geographic factors that, in the investigator's judgment, possibly interfere with scheduled disease assessments, treatment, and follow-up, compromise patient compliance, or place the patient at high risk of treatment-related complications.
  22. Female patients who are pregnant or breastfeeding. Abuse of alcohol, cannabis-derived products, or other controlled substances.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
115 participants (estimated)

Study arms

  • Experimental
    Phase I: Dose Escalation, Phase II: Dose Expansion

    Phase I: Dose Escalation During the dose escalation, the planned starting dose of EMB-07 is 6 mg. A dose escalation scheme of "3+3" will be followed to determine DLT, MTD, and RP2CD. Phase II: Dose Expansion For each cohort: During the dose-expansion, approximately 10 to 15 patients will be enrolled and administrated in each cohort to further characterize the safety profile and anti-tumor activity of the combination therapies. Approximately 20 patients per cohort receiving RP2CD will be pooled from the dose escalation and dose expansion phases to evaluate preliminary efficacy signals.

    Drug: EMB07 · Drug: Rituximab/Gemcitabine/Oxaliplatin

Interventions

  • DrugEMB07

    EMB-07 is a bispecific antibody targeting CD3 and receptor-tyrosine-kinase-like orphan receptor 1 \[ROR1\]

  • DrugRituximab/Gemcitabine/Oxaliplatin

    Rituximab is a monoclonal antibody drug specifically targeting the CD20 antigen. Gemcitabine is a chemotherapy drug classified as an antimetabolite. Oxaliplatin is a platinum-based chemotherapy drug.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) of EMB-07(Phase I only)

    Time frame: Up to 28 days

  2. Rate of Adverse Events (AE) and Serious Adverse Events (SAE)

    Adverse events and serious adverse events as assessed by CTCAE v5.0

    Time frame: From enrollment up to 30 days after the last dose

  3. Recommended phase II dose (RP2D) of EMB-07

    Time frame: Up to 28 days

  4. Objective Response Rate (ORR)

    Objective response rate, measured by Lugano 2014

    Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first, up to 2 years

Secondary outcomes

  1. Duration of Response (DOR)

    Time from first study drug dose to first documented disease progression (per Lugano 2014 criteria) or death from any cause, whichever occurs first.

    Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first; up to 2 years

  2. Duration of Complete Response(DOCR)

    Time from first study drug dose to first documented disease progression (per Lugano 2014 criteria) or death from any cause, whichever occurs first.

    Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first; up to 2 years

  3. Time to Treatment Response(TTR)

    Time from first study drug dose to first documented disease progression (per Lugano 2014 criteria) or death from any cause, whichever occurs first.

    Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first; up to 2 years

  4. Time to Complete Response(TTCR)

    Time from first study drug dose to first documented disease progression (per Lugano 2014 criteria) or death from any cause, whichever occurs first.

    Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first; up to 2 years

  5. Event-Free Survival(EFS)

    Time from first study drug dose to first documented disease progression (per Lugano 2014 criteria) or death from any cause, whichever occurs first.

    Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first; up to 2 years

  6. Progression Free Survival (PFS)

    Time from first study drug dose to first documented disease progression (per Lugano 2014 criteria) or death from any cause, whichever occurs first.

    Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first; up to 2 years

  7. Overall Survival(OS)

    Time from first study drug dose to first documented disease progression (per Lugano 2014 criteria) or death from any cause, whichever occurs first.

    Time frame: From first dose until the date of first documented progression or date of death from any cause, whichever comes first; up to 2 years

  8. Maximum Plasma Concentration (Cmax) of EMB-07

    Maximum observed plasma concentration of EMB-07, quantified by a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay using human plasma samples.

    Time frame: From predose up to 3 months after first dose

  9. Time to Maximum Plasma Concentration (Tmax) of EMB-07

    Time from study drug administration to the time of maximum measured plasma concentration of EMB-07, quantified by validated LC-MS/MS assay using human plasma samples.

    Time frame: From predose up to 30 days after the last dose

  10. Trough Serum Concentration (Ctrough) of EMB-07

    Minimum observed serum concentration of EMB-07, measured immediately prior to the next scheduled dose (trough), quantified by validated LC-MS/MS assay using human serum samples.

    Time frame: From predose up to 30 days after the last dose

  11. Anti-Drug Antibody (ADA) Positive Rate of EMB-07

    Percentage of subjects testing positive for anti-EMB-07 binding antibodies in serum samples, detected by a validated electrochemiluminescence (ECL) immunoassay.

    Time frame: From predose up to 30 days after the last dose

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 26 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 6, 2026
First posted
Feb 25, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07432022
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Feb 25, 2026
Start date
Apr 1, 2026
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Sep 1, 2026

Study contacts

Xikang Xu
Contact
xkxu@epimab.com
86-21-61951000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion